Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
Open Access
- 4 June 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 816
- https://doi.org/10.3389/fphar.2020.00816
Abstract
Nocturia impairs quality of life (QoL). We have performed a non-interventional study in which men with lower urinary tract symptoms (LUTS) were treated for at least 3 months with tamsulosin oral controlled absorption system (0.4 mg q.d.). Other than observing efficacy and tolerability of this drug formulation, the study was designed to explore the relative roles of number of nocturia episodes and of non-urological causes of nocturia on nocturia-related QoL at baseline and treatment-associated changes thereof. The study enrolled 5775 men seeking treatment of their LUTS. Tamsulosin improved LUTS, e.g. International Prostate Symptom Score from 19.5 ± 5.9 to 10.1 ± 4.9 (means ± SD). This was associated by clinically meaningful improvements in the Nocturia QoL score (from 45 ± 19 to 73 ± 17 points) and other QoL scores. Number of nocturnal voids was the key driver of all QoL scores at baseline; change of number of nocturia episodes that of improvement of all QoL scores upon treatment. In contrast, non-urological causes of nocturia such as heart failure, diabetes, sleep apnea, fluid or alcohol intake or use of diuretics or hypnotics had only small if any effects on baseline QoL or treatment-associated improvements thereof. The observed effects of non-urological causes on QoL apparently were largely driven by their effect on number of nocturnal voids. These data further support the idea that improvement of nocturia may be an important treatment goal in male LUTS.Funding Information
- Deutsche Forschungsgemeinschaft
- Boehringer Ingelheim
This publication has 43 references indexed in Scilit:
- Nocturia and Quality of Life: Results from the Boston Area Community Health SurveyEuropean Urology, 2012
- Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) SurveyBJU International, 2011
- Usefulness of Nocturia as a Mortality Risk Factor for Coronary Heart Disease Among Persons Born in 1920 or 1921The American Journal of Cardiology, 2006
- Visual Analog Scale Questionnaire to Assess Quality of Life Specific to Each Symptom of the International Prostate Symptom ScoreJournal of Urology, 2006
- Tamsulosin - modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasiaTherapy, 2006
- Prostate-Specific Antigen as an Estimator of Prostate Volume in the Management of Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2003
- A 6‐month large‐scale study into the safety of tamsulosinBritish Journal of Clinical Pharmacology, 2001
- Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin?BJU International, 2001
- Wirksamkeit und Sicherheit von Alfuzosin SR bei der BPHDer Urologe B, 1998
- TAMSULOSIN TREATMENT OF 19,365 PATIENTS WITH LOWER URINARY TRACT SYMPTOMSJournal of Urology, 1998